The Institute of Cancer Research (ICR) has announced the start of a Phase II clinical trial of a drug named idetrexed, created by scientific teams in its Centre for Cancer Drug Discovery.

The trial will further test the safety and effectiveness of idetrexed in a larger group of patients with ovarian cancer, specifically.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is conducted along with Algok Bio and BTG International, which have partnered with the ICR earlier in the drug’s development.

Algok Bio gained the rights to develop and market idetrexed globally, as part of an exclusive license agreement signed with BTG.

BTG will receive an upfront and tiered royalty payments from Algok Bio along with additional payments upon receiving specific regulatory and sales milestones.

Idetrexed has already demonstrated promising results in ovarian cancer patients in a Phase I trial, led by ICR’s researchers and The Royal Marsden NHS Foundation Trust in London.

The trial treated a total of 109 platinum-resistant ovarian cancer patients with high or medium expression of alpha folate receptor (FRα) with idetrexed.

Nine patients out of 25 who received the recommended phase II dose, showed tumour shrinkage with overall response rate of 36%.

ICR and The Royal Marsden Drug Development co-director and Phase I study principal investigator professor Udai Banerji said: “Idetrexed is a small molecule targeting FRα-overexpressing cancers that has shown significant single agent activity in Phase I clinical trials.

“In a similar stage of development, idetrexed has shown comparable efficacy to drugs such as antibody drug conjugates that have gone on to successful late phase development.”